Business
Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results
Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth Strategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering ...
About this update from Evotec Se
[{"type":"list","items":[{"val":[{"type":"text","content":"Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Strategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering operational excellence","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong Q4 2024 revenue and EBITDA results in spite of challenging market conditions. Full year guidance met, with liquidity significantly improved","length":146,"tagName":"p"}]},{"val":[{"type":"text","content":"Priority Reset on track to deliver annualised recurring gross savings of € 40 m","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"2025 guidance: group revenues to grow 5 - 10 % (€ 840 - 880 m); 2028 outlook foresees revenue CAGR2024-2028 between 8 - 12% and generation of EBITDA margin above 20 %","length":175,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":685,"olType":false},{"type":"text","content":"HAMBURG, GERMANY / ACCESS Newswire / April 17, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced its financial results for FY 2024, provided guidance for FY 2025 and outlook for 2028 reflecting the path to sustainable profitable growth, following the completion of its strategic review process.","length":352,"tagName":"p"},{"type":"text","content":"Dr Christian Wojczewski, Chief Executive Officer of Evotec, said:"Evotec's ambitious new direction paves the way for sustainable profitable long-term growth. We are refocusing Evotec on its core strengths: technology and science leadership, where we deliver maximum impact for customers and patients. By combining cutting-edge technology platforms, disruptive science, and AI-driven innovation, we are accelerating the journey from concept to cure with our partners. We delivered on 2024 financial guidance, and I am excited about the opportunities that lie ahead of us. Together with our talented teams, we are writing the next chapter of Evotec's success story as a drug discovery pioneer."","length":711,"tagName":"p"},{"type":"text","content":"Evotec unveils new strategy to refocus on core strengths and define clear roadmap to sustaina...